Derivation and performance of an end-of-life practice score aimed at interpreting worldwide treatment-limiting decisions in the critically ill

Spyros D. Mentzelopoulos1*, Su Chen2, Joseph L. Nates3, Jacqueline M. Kruser4, Christiane Hartog5,6, Andrej Michalsen7, Nikolaos Efstathiou8, Gavin M. Joynt9, Suzana Lobo10, Alexander Avidan11 and Charles L. Sprung11 on behalf of the End-of-life Practice Score Study Group

Abstract

Background: Limitations of life-sustaining interventions in intensive care units (ICUs) exhibit substantial changes over time, and large, contemporary variation across world regions. We sought to determine whether a weighted end-of-life practice score can explain a large, contemporary, worldwide variation in limitation decisions.

Methods: The 2015–2016 (Ethicus-2) vs. 1999–2000 (Ethicus-1) comparison study was a two-period, prospective observational study assessing the frequency of limitation decisions in 4952 patients from 22 European ICUs. The worldwide Ethicus-2 study was a single-period prospective observational study assessing the frequency of limitation decisions in 12,200 patients from 199 ICUs situated in 8 world regions. Binary end-of-life practice variable data (1 = presence; 0 = absence) were collected post hoc (comparison study, 22/22 ICUs, n = 4592; worldwide study, 186/199 ICUs, n = 11,574) for family meetings, daily deliberation for appropriate level of care, end-of-life discussions during weekly meetings, written triggers for limitations, written ICU end-of-life guidelines and protocols, palliative care and ethics consultations, ICU-staff taking communication or bioethics courses, and national end-of-life guidelines and legislation. Regarding the comparison study, generalized estimating equations (GEE) analysis was used to determine associations between the 12 end-of-life practice variables and treatment limitations. The weighted end-of-life practice score was then calculated using GEE-derived coefficients of the end-of-life practice variables. Subsequently, the weighted end-of-life practice score was validated in GEE analysis using the worldwide study dataset.

Results: In comparison study GEE analyses, end-of-life discussions during weekly meetings [odds ratio (OR) 0.55, 95% confidence interval (CI) 0.30–0.99], end-of-life guidelines [OR 0.52, (0.31–0.87)] and protocols [OR 15.08, (3.88–58.59)], palliative care consultations [OR 2.63, (1.23–5.60)] and end-of-life legislation [OR 3.24, 1.60–6.55)] were significantly associated with limitation decisions (all \(P<0.05\)). In worldwide GEE analyses, the weighted end-of-life practice score was significantly associated with limitation decisions [OR 1.12 (1.03–1.22); \(P=0.008\)].

*Correspondence: sdmentzelopoulos@yahoo.com; sdmentzelopoulos@gmail.com
1 First Department of Intensive Care Medicine, National and Kapodistrian University of Athens Medical School, Evangelismos General Hospital, 45–47 Ipsilandou Street, 10675 Athens, Greece
Full list of author information is available at the end of the article
This work has been presented in part at the 24th Annual Congress (Digital) of the European Society of Intensive Care Medicine, October 3–6, 2021.
Background
End-of-life care is an integral component in the delivery of critical care [1]. Epidemiological data indicate that 15–30% of patients admitted to intensive care units (ICUs) around the world die [2], while 10–12% undergo limitations of life-sustaining treatments [3–5]. Such treatments prolong life without reversing the underlying medical condition; examples include cardiopulmonary resuscitation (CPR), mechanical ventilation and renal replacement therapy [6].

In the past three decades, several studies have focused on the investigation of patients’, families’, physicians’ and nurses’ attitudes or practices regarding life support at the end of life [7–10]. The main concerns were symptom control, patient and family satisfaction, adequate communication and management of conflicts between individuals involved in end-of-life decision-making. Few studies have focused on the formal organizational or system-level support and the existing infrastructure of individual ICUs to assist health care staff to perform end-of-life care at a high standard [11].

The novel end-of-life practice score (EPS) is a 12-component score developed through expert consensus and review of existing literature. The EPS was designed to measure the end-of-life care infrastructure and organization of an ICU. It was first developed to interpret the increases in treatment limitations over time in 22 ICUs situated across Northern, Central and Southern Europe [4]. This was the principal finding of a two-part longitudinal study of ICU end-of-life care delivery, termed “comparison study” from now on. This comparison study had two data collection periods, 16 years apart, in the context of the Ethicus-1 study (1999–2000) and the Ethicus-2 study (2015–2016) [3–5]. Exploratory logistic regression analysis revealed a significant association between the EPS and time-dependent changes in the frequency of treatment limitation decisions [4]. However, the relative contribution of each one of the 12 binary end-of-life practice variables in explaining temporal changes in the frequency of limitation decisions remained unclear.

Using data from the comparison study’s European cohort [4], the current study aimed to first identify specific aspects of end-of-life practice with possibly strong, clinically relevant associations with the comparison study’s time-dependent variations in limitation decisions in European ICUs [4]. The second aim was to develop an EPS with appropriately weighted components. Such weighted EPS might aid in interpreting the recently reported global variation in treatment limitation frequency across 199 ICUs from 8 world regions (worldwide Ethicus-2 study) [5], and potentially have general application in future similar studies. Adequately interpreting this contemporary global variation might help improve end-of-life practice worldwide.

Methods
This study includes data analyses from two previously approved and published studies [4, 5]. Therefore, there was no requirement for ethical approval.

Comparison study summary description
Participating ICUs were in Northern (4 countries), Central (4 countries), and Southern (6 countries) Europe. Center-level and patient-level data were collected prospectively. Data on 4592 patients who died or had a limitation of life-sustaining interventions (2807 and 1785 from the Ethicus-1 and Ethicus-2 studies, respectively) were available [4]. Comparison study and worldwide Ethicus-2 study data forms and collection methodologies were identical [5].

The primary outcome was application of any limitation in life-prolonging therapy (withholding, or withdrawing, or active shortening of the dying process [4]). Patients were categorized into 5 prospectively defined and mutually exclusive end-of-life categories: withholding of life-sustaining therapy, withdrawing of life-sustaining therapy, active shortening of the dying process, failed CPR and brain death [4].

Original (unweighted) EPS development
In the comparison study, 12 end-of-life practice variables (i.e., EPS subcomponents) were collected post hoc from 22 participating ICUs [4]. A simple questionnaire with two possible answers (i.e., no = “absence” or yes = “presence”) for each practice variable was administered electronically. These variables reflect key aspects of ICU end-of-life practice [4, 5] and include (1) routine family meetings [12–14], (2) daily deliberation for appropriate level of care [12], (3) end-of-life discussions during family meetings [12], (4) written triggers for treatment
limitations [15, 16], (5–6) written end-of-life guidelines [17] and protocols [15], (7) palliative care consultations [14, 18], (8) ethics consultations [12, 14], (9–10) staff taking communication or bioethics courses [12–14, 18] and (11–12) country end-of-life guidelines or legislation [12, 17, 18]. Variables were graded by 0 or 1 according to their reported absence or presence, respectively. The sum of these grades was the “original” EPS, which ranged within 0–12. Thus, the higher the EPS the more end-of-life practices were concurrently present. Definitions of practice variables and the EPS are presented in Table 1. The same post hoc collection of binary end-of-life practice data was performed for the Ethicus-2 worldwide study [5].

**Derivation of the weighted EPS**

The comparison study showed a substantial increase in treatment limitations’ frequency over time and a decrease in the frequency of death without limitation [4]. This was considered as a time-dependent improvement in end-of-life practices [19]. To determine the relative importance of each end-of-life practice variable as explanatory variable, generalized estimating equations (GEE) analysis with robust standard errors and an exchangeable working correlation structure accounting for the factor center [5] was applied to the entire comparison study population [4]. Additional explanatory variables included study period (i.e., 2015–2016 vs. 1999–2000), region (i.e., Northern, Central and Southern Europe), age, gender, acute ICU admission diagnoses, chronic diseases and physician religion. Type of model was set at “binary logistic.” The binary dependent variable was patients with “any treatment limitation or no treatment limitation” (Fig. 1). For these patient-level analyses, it was assumed that a specific, ICU-level grading of an end-of-life practice variable should correspond to all patients originating from that ICU. For example, if an ICU contributed 100 patients and the site principal investigator responded positively to “end-of-life discussions during weekly meetings”-meaning that this was a typical ICU-level characteristic-then “end-of-life discussions” were assumed to have occurred for all the 100 participants of that ICU [4].

Comparison study GEE model was cross-validated using the fivefold validation technique [20]. More specifically, the entire study dataset was randomly split into five, equally-sized groups, i.e., the fivefolds, with one of the folds (20% of the data) serving as the validation group and the remaining four folds (80% of the data) serving as the training group for constructing probabilistic models. The model was fit on the training group, and its coefficient estimates were used to predict treatment limitation probability in the validation group. This process was followed five times in total; each time, a different fold was used as validation group [20, 21]. Agreement (calibration) between predicted and observed treatment limitations in the validation group was assessed by constructing a receiver operating characteristic (ROC) curve based on the entire dataset and calculating the “area under the curve” (AUC).

**Weighted EPS rescaling and validation**

Patient-level GEE analysis accounting for center on the worldwide Ethicus-2 dataset (n = 11,574) included a weighted EPS and the following explanatory variables: world region (i.e., Africa, Latin America, North America, Asia, Australia/New Zealand and Northern, Central and Southern Europe), age, gender, acute ICU admission diagnoses, chronic diseases, and center-type (i.e., private vs. public) (worldwide model 1; Fig. 1). The worldwide dataset did not include brain-dead patients, and the dependent variable remained “limitation yes/no” [5], reflecting treatment limitation vs. failed CPR. Weighted EPS was calculated by multiplying the 0 or 1 end-of-life practice variable response grades by the GEE coefficients determined in the comparison study data analysis and summing up the resulting 12 end-of-life practice variable-specific products (Table 1). Consequently, the weighted EPS was derived according to both the presence and relative importance of its subcomponents. Subsequently, EPS’s values were linearly transformed (i.e., rescaled) to its original 0–12 range [4] (Table 1).

Three additional GEE models were fit on the worldwide study data, namely a recently reported worldwide model 2 [5] and 2 additional models, i.e., worldwide models 3 and 4. Worldwide model 2 differed from worldwide model 1 in including the 12 end-of-life practice variables as separate explanatory variables instead of the EPS [5] (Fig. 1). Worldwide model 3 (reference model) included all the explanatory variables of models 1 and 2, besides the EPS or the end-of-life practice variables (Fig. 1). Worldwide model 4 included the variables of worldwide model 3 plus the original, unweighted EPS version (i.e., the simple sum of the 1/0 grades of the end-of-life practice variables [4, 5]) (Fig. 1). Weighted EPS validation was the primary aim of the fitting of worldwide model 1. The purpose of the additional fitting of worldwide models 2–4 was to comparatively determine any potential weighted EPS-associated improvement in GEE model performance. Analyses were designed by SDM, SC and JN.

All models were subjected to fivefold cross-validation. Furthermore, for all worldwide models, ROC construction and corresponding AUC determinations were used to assess agreement between predicted and observed treatment limitations in the validation groups. Finally, goodness of fit was compared between worldwide models.
Table 1 Definitions of subcomponent variables of end-of-life practice score and derivation of its weighted/rescaled form

| EOL practice variable                                      | Definition                                                                                                                                                                                                 |
|------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Routine family meetings                                   | Regular (i.e., on admission and at least twice a week) scheduled conferences of at least one member of an ICU patient's family and at least one member of the treating team aimed at (a) determining/clarifying the patient’s health status, and comorbidities, (b) patient values, preferences, and goals concerning treatment options; and (c) conveying honest, accurate, and evidence-based information about patient clinical status and current/updated prognosis |
| Daily deliberation for appropriate level of care           | Routine daily discussions among members of the ICU treating team aimed at confirming that medical/surgical interventions administered to a patient are not disproportionate and/or do not contradict his/her preferences |
| EOL discussions during family meetings                    | Conferences (on admission, and followed up at least as appropriate/feasible) of at least one member of an ICU patient’s family and at least one member of the treating team aimed at determining and/or revising/adjusting EOL treatment goals according to the evolution of the patient’s clinical course and (particularly changes) of prognosis, and ‘previously clarified’ EOL values/preferences. This variable focuses on a specific type of family meetings’ content aimed at achieving consistency between patient wishes and provided EOL care |
| Written ICU triggers for limitations                      | A set of written, pre-specified medical and/or bioethical criteria for limiting LSTs in the ICU. Examples of such criteria may include: family request, presence of a pertinent living will that has to be respected, irreversible condition, un-survivable injury, severe brain injury with poor prognosis (e.g., minimally conscious state, high Sequential Organ Dysfunction Assessment Score plus poor response to acute illness treatment, multiple organ failure (≥ 3 organs), non-beneficial therapy, and terminal illness |
| Written ICU EOL guidelines                                | Written ICU recommendations (e.g., shared decision-making, or obligation to inform the family about poor patient response to treatment, and/or lack of expected benefit from available and/or ongoing LSTs), with a written expectation to be followed for EOL decision-making and application of EOL decisions |
| Written ICU EOL (symptom management) protocols            | A written set of ICU recommendations and standards aimed at preventing any kind of patient distress (e.g., pain, dyspnea, delirium) during the application of LST limitation decisions on withholding and/or withdrawing of LSTs; written ICU EOL protocols may be based on recent, pertinent recommendations on how to perform withdrawing of LSTs |
| Palliative care consultations                             | Consultations and/or liaison with specialists from the hospital’s (specifically designated) palliative care service, focused on the treatment of symptoms (e.g., dyspnea, pain, or delirium), rather than the treatment of any underlying disease processes. Psychosocial and spiritual needs may also be attended to in patients who do not require sedation and are able to communicate. Such consultations may take place whenever LST limitation is considered, in the context of communication of available treatment options to the patient/family. An exception to the former requirement pertains to the presence of an intensivist with palliative care expertise in the ICU treating team |
| Ethics consultations                                      | Consultations and/or liaison with a specialist from the hospital’s (specifically designated) clinical ethics committee, focused on addressing of any ensuing ethical dilemmas and/or challenges, including disagreements (that cannot otherwise be resolved) between surrogate decision-makers, between the patient/family and the ICU treating team, health care professionals or others |
| Communication courses                                     | Lessons focused at developing or improving the capability of (1) expressing oneself clearly, honestly, and accurately (about available treatment options), and also in a way that is readily understood by the patient/family; and (2) providing psychological support, and showing empathy to the patient/family |
| Bioethics courses                                          | Lessons focused on improving the knowledge, understanding of the widely accepted four Principles of Bioethics, and/or the capability of effectively addressing ethical dilemmas and challenges of routine clinical practice |
| Country EOL guidelines                                     | Written recommendations by national medical societies, or statutory governing bodies, for EOL decision-making and EOL practices (e.g., symptom control and/or procedure for withdrawal of mechanical ventilation) in the ICU |
| Country EOL legislation                                    | A set of laws aimed at addressing commonly ensuing ethical issues as part of routine clinical practice (e.g., Should advance directives always be followed? Are withholding or withdrawing of LSTs, or active shortening of the dying process legally allowed?, etc.) |
| EOL practice score                                         | The sum of binary (i.e., 0 or 1) grading of the 12 EOL practice variables according to their absence (x = 0) or presence (x = 1), score range: 0–12 |
| Weighted EOL practice score                                | Sum of products of EOL practice variable grades and GEE coefficients derived from the GEE analysis of the comparison study data (see also “Methods”), sum actual range: −2.574 to 5.706 |
| Weighted EOL practice score rescaled to a 0 to 12 rangea    | Weighted/rescaled EOL practice score = (12/(5.706 + 2.574)) * (actual weighted EPS + 2.574) |

*a* This transformation was undertaken, in order to simplify/facilitate the interpretation of the weighted EPS odds ratio determined in the GEE analyses of the worldwide study data

ICU intensive care unit, EOL end-of-life, LST life-sustaining treatment, GEE generalized estimating equations
1, 2, and 4 vs. reference model 3 using the “analysis of variance (ANOVA)” function in R (Fig. 1).

EPS and failed CPR worldwide study data were compared among regions by Kruskal Wallis test and Pearson chi square test, respectively. All analyses were conducted with R (version 4.0.2). GEE analysis was conducted with R package geepack and Figures were produced using R package pROC [22]. Figure 1 is a summary illustration of the above-described analytic methodology. Additional methodological details are presented in Additional file 1.

Results

GEE model for weighted EPS derivation

Data from 4592 patients were included in the comparison study’s GEE model. Patient characteristics have been reported elsewhere [4] and are presented in Additional file 1: Table S1.

Table 2 displays comparison study GEE results (Ethicus-2 vs. Ethicus-1), which reconfirm that the 2015–2016 Ethicus-2 cohort was strongly associated with treatment limitation [odds ratio (OR): 36.3, (95% confidence interval): (9.1–144.5)]; patient age, physician religion, and acute diagnoses/chronic diseases were also associated with limitation decisions. Among end-of-life practice variables, end-of-life discussions during weekly meetings [OR 0.55, (0.30–0.99)], written ICU end-of-life guidelines [OR 0.52, (0.31–0.87)], written ICU end-of-life protocols [OR 15.08, (3.88–58.59)], palliative care consultations [OR 2.63, (1.23–5.60], and national end-of-life legislation [OR 3.24, (1.60–6.55)] were significantly associated with limitation decisions. The AUC of the comparison study model was 0.865 after applying fivefold cross-validation (Fig. 2).

GEE model for weighted EPS validation

In the worldwide study cohort, EPS/end-of-life practice variable data were available from 186/199 participating ICUs (93.5%), corresponding to 11,574 patients who died or had a treatment limitation [5]. Baseline characteristics of worldwide study participants are presented in Additional file 1: Table S2. Regional and overall original and
## Table 2  Comparison study general estimating equations model for “any treatment limitation or no treatment limitation”

|                          | Estimate | OR     | 95% CI       | P value |
|--------------------------|----------|--------|--------------|---------|
|                          |          | Lower  | Upper        |         |
| Ethicus 2 study (2015–2016) vs. Ethicus 1 study (1999–2000) | 3.59     | 36.29  | 9.12        | 144.47  | <0.001 |
| **Region**               |          |        |              |         |
| Central Europe vs. Northern Europe | −0.20   | 0.82   | 0.42     | 1.59  | 0.56   |
| Southern Europe vs. Northern Europe | −1.13   | 0.32   | 0.15     | 0.68  | 0.003  |
| **Age**                  |          |        |              |         |
|                          | 0.03     | 1.02   | 1.02     | 1.03  | <0.001 |
| **Sex, female vs. male** | −0.02    | 0.98   | 0.89     | 1.07  | 0.62   |
| **Physician religion**   |          |        |              |         |
| Catholic vs. none        | 0.64     | 1.89   | 1.19     | 3.00  | 0.007  |
| Jewish vs. none          | 1.04     | 2.83   | 1.48     | 5.41  | 0.002  |
| Greek orthodox vs. none  | 0.55     | 1.74   | 0.97     | 3.10  | 0.06   |
| Protestant vs. none      | 0.87     | 2.39   | 1.42     | 4.04  | 0.001  |
| Unknown vs. none         | −6.03    | 0.002  | 0.001    | 0.010 | <0.001 |
| Other vs. none           | 0.26     | 1.30   | 0.75     | 2.25  | 0.35   |
| Islam vs. none           | 0.41     | 1.51   | 0.63     | 3.60  | 0.35   |
| **Acute diagnoses**      |          |        |              |         |
| Surgery vs. neurologic   | −0.13    | 0.88   | 0.62     | 1.23  | 0.45   |
| Respiratory vs. neurologic | 0.49    | 1.64   | 1.16     | 2.32  | 0.006  |
| Cardiovascular vs. neurologic | −0.19  | 0.83   | 0.62     | 1.11  | 0.22   |
| Gastrointestinal vs. neurologic | 0.68   | 1.98   | 1.40     | 2.81  | <0.001 |
| Metabolic vs. neurologic | 0.70     | 2.01   | 1.00     | 4.06  | 0.0502 |
| Hematologic vs. neurologic | 0.48    | 1.62   | 0.71     | 3.74  | 0.26   |
| Trauma vs. neurologic    | −0.32    | 0.73   | 0.51     | 1.05  | 0.09   |
| Sepsis vs. neurologic    | 0.65     | 1.92   | 1.25     | 2.94  | 0.003  |
| Other vs. neurologic     | 0.51     | 1.66   | 1.00     | 2.74  | 0.048  |
| **Chronic diseases**     |          |        |              |         |
| Cardiovascular diseases vs. none | 0.56    | 1.75   | 1.40     | 2.18  | <0.001 |
| Neurological-cognitive diseases–muscular vs. none | 0.74    | 2.09   | 1.25     | 3.48  | 0.005  |
| Chest diseases vs. none  | 0.91     | 2.48   | 1.80     | 3.40  | <0.001 |
| Kidney and urinary system diseases vs. none | 0.38    | 1.47   | 0.88     | 2.44  | 0.14   |
| Digestive system vs. none | 1.49    | 4.46   | 2.72     | 7.29  | <0.001 |
| Immunologic system vs. none | 0.93    | 2.53   | 1.49     | 4.30  | 0.001  |
| General history vs. none | 0.43     | 1.54   | 1.14     | 2.07  | 0.005  |
| Cancer vs. none          | 1.17     | 3.23   | 2.15     | 4.83  | <0.001 |
| Unknown vs. none         | 1.30     | 3.67   | 1.56     | 8.65  | 0.003  |
| **End-of-life practice variables** |          |        |              |         |
| Routine ICU family meetings: yes vs. no | −0.03   | 0.97   | 0.52     | 1.79  | 0.91   |
| Daily deliberation for appropriate level of ICU care: yes vs. no | 0.57    | 1.77   | 0.96     | 3.28  | 0.07   |
| End-of-life (EOL) discussions during weekly (family) meetings: yes vs. no | −0.61   | 0.55   | 0.30     | 0.99  | 0.047  |
| Written triggers for limitations: yes vs. no | −0.14   | 0.87   | 0.41     | 1.86  | 0.72   |
| Written ICU EOL guidelines: yes vs. no | −0.65   | 0.52   | 0.31     | 0.87  | 0.013  |
| Written ICU EOL protocols: yes vs. no | 2.71    | 15.08  | 3.88     | 58.59 | <0.001 |
| Palliative care consultations: yes vs. no | 0.97    | 2.63   | 1.23     | 5.60  | 0.012  |
| Ethics consultations: yes vs. no | −0.96   | 0.38   | 0.14     | 1.07  | 0.07   |
| ICU staff taking communication courses: yes vs. no | 0.13    | 1.14   | 0.52     | 2.51  | 0.74   |
| ICU staff taking bioethics courses: yes vs. no | −0.19   | 0.83   | 0.19     | 3.57  | 0.80   |
| Country EOL guidelines: yes vs. no | 0.14    | 1.16   | 0.53     | 2.50  | 0.72   |
| Country EOL legislation: yes vs. no | 1.17    | 3.24   | 1.60     | 6.55  | 0.001  |
| Intercept                | −1.54    | 0.21   | 0.08     | 0.59  | 0.003  |

Patient data originate from the entire comparison study population (n = 4592) (4)

CI: confidence interval, OR: odds ratio. Collinearity assessment: variance inflation, 1.03–4.29; condition index, 30.75
weighted/rescaled EPS values and frequency distribution of failed CPR are presented in Table 3.

Worldwide GEE models 1, 2, and 3 and 4 are presented in Table 4, and Additional file 1: Tables S3, S4 and S5, respectively. As also elsewhere reported [5], region, age, acute diagnoses/chronic diseases and center type were associated with limitation decisions in all GEE models. In worldwide model 1, weighted/rescaled EPS was an independent predictor of treatment limitation [OR 1.12, (1.03–1.22)] (Table 4: EPS data highlighted in bold), i.e., for each 1-point increment in weighted/rescaled EPS, treatment limitation probability increased by 12%.

The AUCs of worldwide models 1, 2, 3, and 4 were 0.745, 0.752, 0.727, and 0.730, respectively (Fig. 3). Between-model comparisons (by R's "ANOVA") demonstrated that only the worldwide model 1 had significantly better goodness of fit vs. the reference model (P = 0.008). In contrast, the goodness of fit of worldwide models 2 and 4 was not significantly better when compared to the reference model (P = 0.056–0.23) (Fig. 3).

**Additional exploratory analyses**

In the worldwide study population [5], presence of country end-of-life legislation and/or combined presence of end-of-life practice variables with significant ORs (see also above and Table 2) was associated with failed CPR frequencies of 8.4–9.4%, whereas upper-quartile weighted/rescaled EPS of ≥ 8.22 was associated with a failed CPR frequency of < 8% (Table 5). Region-level proportions of "raw" positive responses to the 12 end-of-life practice variables for both the comparison and worldwide studies [4, 5] are provided in Additional file 1: Table S6. In the comparison study [4], maximal European regional increases over time in positive responses for end-of-life protocols, palliative care consultations, and end-of-life legislation amounted to 50%; the respective maximal differences in the positive responses of the worldwide study [5] varied within 68–100%.

Worldwide, country-level, weighted/rescaled EPS data are shown in Additional file 1: Figure S1.

**Discussion**

A novel end-of-life practice score for ICUs, the EPS, weighted according to the strength of the associations of its subcomponents with limitation decisions, was derived

---

**Table 3 Regional end-of-life practice score and frequency of failed cardiopulmonary resuscitation**

| Region                  | No. of centers | No. of patients | Original EPS median (IQR) a | W/R EPS median (IQR) a | No. (%) of failed CPR b |
|-------------------------|----------------|----------------|-----------------------------|------------------------|------------------------|
| Africa                  | 2              | 160            | 2 (2–7)                     | 3.67 (3.56–3.67)       | 106 (66.3)             |
| Latin America           | 9              | 501            | 6 (3–7)                     | 4.70 (4.70–7.47)       | 154 (30.7)             |
| North America           | 9              | 910            | 9 (9–12)                    | 8.76 (8.24–8.76)       | 78 (8.6)               |
| Asia                    | 28             | 1690           | 7 (4–7)                     | 5.56 (3.96–7.03)       | 253 (15.0)             |
| Australia/New Zealand   | 9              | 513            | 8 (7–8)                     | 7.80 (5.73–9.81)       | 23 (4.5)               |
| Central Europe          | 41             | 3494           | 7 (6–9)                     | 6.47 (5.46–8.24)       | 402 (11.5)             |
| Northern Europe         | 35             | 2055           | 7 (6–9)                     | 5.72 (4.41–7.43)       | 70 (3.4)               |
| Southern Europe         | 53             | 2251           | 6 (4–9)                     | 5.51 (4.24–7.02)       | 553 (24.6)             |
| Total                   | 186            | 11,574         | 7 (6–9)                     | 6.28 (4.50–8.22)       | 1,639 (14.2)           |

EPS end-of-life practice score, IQR interquartile range, CPR cardiopulmonary resuscitation, W/R weighted/rescaled

a Monte Carlo significance level of Kruskal Wallis test among the eight world regions, P < 0.001

b Significance level of "overall" Pearson chi square test among the eight world regions, P < 0.001
from data obtained from a large ethical comparison study [4]. The weighted EPS was rescaled to 0–12, to align with the originally proposed score, and subsequently validated as explanatory variable for treatment limitation decisions using data from a larger worldwide study of end-of-life decision-making [5]. A high EPS was best achieved by ensuring combined presence of the three end-of-life practice variables with the highest coefficient estimates in the comparison study’s GEE analysis, namely the presence of end-of-life ICU protocols, palliative care consultations and national end-of-life legislation. Notably, in a hypothetical case of concurrent positive responses for these variables and negative responses for the remaining 9 variables, the weighted/rescaled EPS-value would amount to 10.76, which is quite close to its maximum value of 12.00. The results from the worldwide study’s data suggest that regions with a high weighted/rescaled EPS demonstrate increased frequency of life-support limitation, and a reduction in failed CPR. Indeed, an upper-quartile EPS was associated with failed CPR rates of < 8%.

Table 4 Worldwide general estimating equations model 1 for “treatment limitation vs. failed cardiopulmonary resuscitation.”

| Region                                | Estimate | OR    | 95% CI Lower | 95% CI Upper | P value |
|---------------------------------------|----------|-------|--------------|--------------|---------|
| America Latin vs. Africa              | 1.90     | 6.66  | 0.81         | 54.94        | 0.08    |
| America Northern vs. Africa           | 2.58     | 13.20 | 1.47         | 118.28       | 0.02    |
| Asia vs. Africa                       | 2.57     | 13.10 | 1.73         | 98.89        | 0.013   |
| Australia/New Zealand vs. Africa      | 3.31     | 27.35 | 3.32         | 225.03       | 0.002   |
| Europe Central vs. Africa             | 2.20     | 9.02  | 1.20         | 67.81        | 0.03    |
| Europe Northern vs. Africa            | 3.80     | 44.83 | 5.89         | 341.23       | < 0.001 |
| Europe Southern vs. Africa            | 2.05     | 7.79  | 1.05         | 58.08        | 0.045   |
| Age                                   | 0.01     | 1.01  | 1.01         | 1.02         | < 0.001 |
| Sex, female vs. male                  | 0.05     | 1.05  | 0.95         | 1.16         | 0.37    |
| Acute diagnoses                       |          |       |              |              |         |
| Surgery vs. neurologic                | −0.53    | 0.59  | 0.48         | 0.72         | < 0.001 |
| Respiratory vs. neurologic            | −0.54    | 0.58  | 0.49         | 0.70         | < 0.001 |
| Cardiovascular vs. neurologic         | −1.01    | 0.36  | 0.29         | 0.45         | < 0.001 |
| Gastrointestinal vs. neurologic       | −0.45    | 0.64  | 0.50         | 0.81         | < 0.001 |
| Metabolic vs. neurologic              | −0.52    | 0.60  | 0.43         | 0.83         | 0.002   |
| Hematologic vs. neurologic            | −0.70    | 0.50  | 0.36         | 0.69         | < 0.001 |
| Trauma vs. neurologic                 | −1.11    | 0.33  | 0.22         | 0.49         | < 0.001 |
| Sepsis vs. neurologic                 | −0.61    | 0.54  | 0.45         | 0.67         | < 0.001 |
| Other vs. neurologic                  | −0.99    | 0.37  | 0.25         | 0.55         | < 0.001 |
| Chronic diseases                      |          |       |              |              |         |
| Cardiovascular diseases vs. none       | 0.13     | 1.14  | 0.95         | 1.36         | 0.17    |
| Neurological-cognitive diseases–muscular vs. none | 0.57     | 1.77  | 1.38         | 2.28         | < 0.001 |
| Chest vs. none                        | 0.38     | 1.46  | 1.16         | 1.84         | 0.001   |
| Kidney vs. none                       | 0.14     | 1.15  | 0.88         | 1.50         | 0.31    |
| Digestive system vs. none             | 0.47     | 1.60  | 1.22         | 2.09         | 0.001   |
| Immunologic system vs. none           | 0.33     | 1.39  | 0.95         | 2.05         | 0.09    |
| General history vs. none              | 0.24     | 1.28  | 1.02         | 1.60         | 0.04    |
| Cancer vs. none                       | 0.53     | 1.70  | 1.33         | 2.17         | < 0.001 |
| Unknown vs. none                      | −0.26    | 0.77  | 0.56         | 1.07         | 0.12    |
| Center type (private vs. public)      | −0.57    | 0.57  | 0.33         | 0.98         | 0.04    |
| Weighted and rescaled end-of-life practice score | **0.12** | **1.12** | **1.03** | **1.22** | **0.008** |
| Intercept                             | −1.94    | 0.14  | 0.02         | 1.11         | 0.06    |

Patient data originate from the entire worldwide study population (n = 11,574) [5]. The comparison-study [4] derived, weighted and rescaled end-of-life practice score is included as explanatory variable (see also Methods). CI, confidence interval; OR, odds ratio. Collinearity assessment: variance inflation, 1.01–1.18; condition index, 18.32. The results on the variable of interest, i.e. the end-of-life practice score, are highlighted in bold.
In comparison study’s analyses, palliative care consultations had the third highest OR for predicting limitation decisions and the third highest coefficient in EPS weighting. Currently, palliative care is widely recognized as a key component of patient/family centered ICU care [13, 14, 19, 23–32]. Nevertheless, our data and other findings reveal that the presence of ICU-based palliative care may substantially vary across world regions (current study’s...
range: 21–89%, corresponding to 68% variation), countries and hospitals [4, 5, 19, 33–36], and even among physicians working in the same ICU [37, 38], or according to daily ICU bed pressure [39].

Four systematic reviews suggested that consultative or integrative palliative care interventions may reduce ICU/hospital length of stay and cost, without increasing mortality [23–26]. Educational interventions aimed at ICU staff, and interventions comprising screening for palliative care referral, goals-of-care discussions and specialist palliative care involvement were associated with significant increases in limitation of life-sustaining treatments and CPR [26]. However, review findings were limited by study quality, heterogeneity of interventions/outcomes and uncertainty about generalizability [23–26].

Randomized trials of palliative care-led family meetings or complex, integrative interventions targeted at clinicians reported neutral and/or negative results, including worsening of post-traumatic stress disorder (PTSD) symptoms [26, 40, 41]. Conversely, randomized trials of multi-component interventions delivered by an interdisciplinary ICU team or of early-triggered palliative care consultations reported mainly positive results, including better clinician-family communication, more limitations in life-sustaining treatments and transitions to hospice care, shorter ICU stay or decreased ICU resource utilization and no significant effect on in-hospital mortality [42, 43]. Published data and current results support the need for further, evidence-based integration of well-designed and multifaceted palliative care interventions in standard ICU care [26]. Such interventions should result in timely provision of effective physical, psychological and spiritual comfort care by specifically trained/skilled ICU clinicians and/or palliative care specialists.

According to our findings, end-of-life protocols in the context of withdrawing or withholding life-sustaining measures should be considered a positive factor during the terminal period of provision of effective palliative care. End-of-life protocol application should be supported by a weighted shared decision that continuation of life-sustaining treatments would confer more harm than benefit to the individual patient [13, 14, 44–46]. End-of-life protocols should focus on the prevention/amelioration of any associated distressful patient symptoms (e.g., pain, dyspnea, or delirium) and minimization/prevention of any potential long-term psychological impact to family members (e.g., post-traumatic stress disorder, anxiety, depression, and complicated grief [16, 44, 45]). A preceding roundtable conference concluded that withdrawing of treatments such as mechanical ventilation should be tailored to individual patient needs [47]. A recent systematic review reported a worldwide variation and ambiguity of practices of withdrawal of mechanical ventilation [45]. Nevertheless, in countries from world regions with high (e.g., 100%) positive response rates for end-of-life protocols (e.g., USA), the quality of dying and death has also been rated high by families of decedent ICU patients [48]. Global variation in end-of-life protocol use is consistent with the worldwide study’s data, although the substantial temporal increase observed in the comparison study suggests that implementation remains dynamic and is evolving with time.

In several countries, the potential for exposure to legal risk may prevent ICU physicians from limiting invasive treatments (including CPR) in patients with poor prognosis [49]. End-of-life legislation is a well-established key factor not only for the prevention of disproportionate treatments [44], but also for the development of interprofessional decision-making and consensus building.
practices that take into account the patient’s values, goals and preferences, and ameliorate the moral distress associated with end-of-life decisions [46, 50]. Notably, legislative processes may be protracted, depending on cultural, religious, social, linguistic and political barriers, and the presence/intensity of lobbying/support by groups of stakeholders and members of regulatory bodies [51–53]. Furthermore, the implementation of in-force laws may still be limited due to lack of awareness, perceived ambiguity, or non-compliance by involved parties (e.g., healthcare professionals) [54, 55]. Nevertheless, the enactment of end-of-life legal frameworks, followed by the development of multifaceted end-of-life care programs/initiatives with electronic infrastructure (e.g., the Physician Orders for Life-Sustaining Treatments [56]) has been shown to substantially promote concordance between recorded patient wishes and administered end-of-life treatments and care [18, 57–59]. Our results confirm this relationship, as a strong association between end-of-life legislation and treatment limitation [5] was observed in all analyses.

Increased rates of limitation and consequent reduction in failed CPR may imply a higher quality of end-of-life care, strictly in the context of the concurrent presence of the above-discussed end-of-life practices and legal support. Nevertheless, decisions on life-support/CPR should still be individualized, taking into account patient prognosis and preferences. The Ethicus study protocol [3–5] did not include any collection of patient-level data on the fulfilment of criteria for withholding or withdrawing CPR [20].

End-of-life practice variable data were not uniformly consistent. Notably, in the comparison study analyses, end-of-life discussions and departmental end-of-life guidelines were negatively associated with treatment limitations. Recently reported limitations of clinician-family end-of-life conferences include insufficient information exchange about the patient’s values and preferences and deficient deliberation; this implies that the communication skills of clinicians need to be improved [18, 59]. Regarding guidelines per se, these may not effectively address problems of reaching consensus decisions, prognostication challenges, barriers in communication, patient palliative care needs, and physician-related variability in end-of-life decision-making [58–62]. Absence of association or negative associations between a number of the end-of-life practice variables and treatment limitation were noted, and appear to be counter-intuitive and difficult to explain. A possible explanation is that in the presence of end-of-life ICU protocols, palliative care consultations, and national end-of-life legislation, other local end-of-life practices may become somewhat redundant. Nevertheless, these local practices may also improve end-of-life care [12–18, 63] and should therefore be retained in the EPS, for further development in validation studies. Collectively, our results on the relative importance of 12 end-of-life practices highlight the need for further, high-quality research based improvement in interventions related to communication, ethics consultations, education, palliative care, and advance care planning or goals-of-care discussions [26]. The resulting progress in end-of-life practice might then be quantifiable by concurrent changes in the weighting of the corresponding EPS subcomponents.

Current results may also indicate the need for further evaluation and improvement of currently accepted end-of-life practices [5]. The establishment of EPS/end-of-life care Registries might facilitate the periodic (e.g., biyearly) determination of potential, time-dependent changes in the associations between the 12 end-of-life practice variables and treatment limitation. This should enable EPS reweighting (and subsequent prospective validation) according to the evolution of end-of-life care, thereby maintaining and/or enhancing its potential usefulness as a simple tool for continuous assessment and improvement of end-of-life care.

Strengths of the current analyses include using robust analytic methodology and large datasets to derive and validate the weighted/rescaled EPS. Limitations include the post hoc EPS data collection, which may have introduced recall and/or social desirability bias [4, 5]. Also, for the purpose of analyses, ICU-level responses for end-of-life practice variables were assumed to uniformly reflect individual patient-level practice; pertinent consequences could include (1) biased results on end-of-life practices with known, patient-level, qualitative variability (e.g., end-of-life discussions) [59], and (2) additional bias due to potential, physician-related variability in end-of-life practice [62, 64]. Nevertheless, our comparison study analysis was actually adjusted for physician religion, which partly explains end-of-life practice variation [3, 64]. Additional limitations comprise uncertainty about the validity and reliability of end-of-life practices derived by expert consensus, absence of prospective EPS validation and lack of data on patients not admitted to the ICU in the context of treatment limitation decisions in hospital wards [4, 5]. Potential perception and measurement bias cannot be excluded, since the presence of the variables was determined by subjective perception. Lastly, only physicians were asked and not nurses or patients/family members.
Conclusions
A weighted/rescaled EPS developed on the basis of changes in limitation decisions over a 16-year period [4] partly explained the substantial variation in contemporary treatment limitation decisions observed in the worldwide study [5]. The most important weighted/rescaled EPS components were ICU end-of-life protocols, palliative care consultations, and country end-of-life legislation. ICUs wishing to improve quality of end-of-life care may consider introducing the palliative care and end-of-life protocols into their organizational structures. Furthermore, national lawmakers might consider establishing and/or improving country-specific end-of-life legislations and healthcare policies targeted at facilitating their implementation.

Abbreviations
ICU: Intensive care unit; EPS: End-of-life practice score; CPR: Cardiopulmonary resuscitation; GEE: Generalized estimating equations; ROC: Receiver operating characteristic curve; AUC: Area under curve; ANOVA: Analysis of variance; OR: Odds ratio.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s13054-022-03971-9

Acknowledgements
Guarantor statement: Full access to all of the data in the study and responsibility for the integrity of the data and the accuracy of the data and analysis: Mentzelopoulos. The members of the End-of-life Practice Score Study Group not listed in the byline of the current submission are the following: 1] Wesley Ely, MD, Co-Director of the Critical Illness, Brain Dysfunction, and Survivorship (CIBS) Center, Professor of Medicine and Critical Care, VA GRECC and Vanderbilt University Medical Center; 2] Erwin J.O. Kompanje, PhD, Department of Intensive Care, Erasmus MC University Center, the Netherlands; 3] Mervyn Mer, MD PhD, Department of Medicine, Divisions of Critical Care and Pulmonology, Charlotte Maxeke Johannesburg Academic Hospital and Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; 4] Charles Feldman, DSc, Distinguished Professor of Pulmonology, Department of Internal Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; 5] Victoria Metaxa, MD, PhD, Department of Critical Care, King’s College Hospital NHS Foundation Trust, London, UK; 6] Myrick C. Shinall, MD, PhD, Vanderbilt University Medical Center; 7] John Myburgh, MD Director, Critical Care Program Professor of Intensive Care Medicine, Faculty of Medicine, University of New South Wales Senior Intensive Care Physician, St George Hospital, Sydney; 8] Chariklia S. Vrettou, MD, PhD, First Department of Intensive Care Medicine, National and Kapodistrian University of Athens Medical School, Evangelismos General Hospital, Athens, Greece.

Author contributions
Study concept: SDM, JLN, SC. Study Design: All authors. Acquisition of Data: SDM, JLN, CH, AM, GMI, SL, AA, and CLS. Drafting of the manuscript: SDM. Critical revision of the manuscript for important intellectual content: all authors. Statistical analyses: SC, SDM. Study supervision: SDM, JLN, CLS. All authors read and approved the final manuscript.

Funding
The article processing charge has been partly covered by the Special Account for Research Funds of the National and Kapodistrian University of Athens Greece (in support of Dr. Mentzelopoulos). Dr. Kruser is supported by Grant # K23HL146890 of the United States National Institute of Health (NIH)/National Heart, Lung, and Blood Institute (NHLBI).

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations
Ethics approval and consent to participate
This study includes data analyses from two previously approved and published studies [4, 5]. Therefore, there was no requirement for ethical approval.

Consent for publication
Not applicable.

Competing interests
There is no disclosure to be made by anyone of the authors regarding any conflict of interest.

Author details
1 First Department of Intensive Care Medicine, National and Kapodistrian University of Athens Medical School; 2] Charité Universitätsmedizin Berlin; 3] Critical Care Department, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; 4] Critical Care Division – Faculty of Medicine São José do Rio Preto, São Paulo, Brazil.
5 Department of Peace-Signaling and Intensive Care Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; 6] Department of Anesthesiology, Critical Care, Emergency Medicine, and Pain Therapy, Konstanz Hospital, Konstanz, Germany; 7] Department of Anesthesiology, Critical Care, Emergency Medicine, and Pain Therapy, Konstanz Hospital, Konstanz, Germany; 8] Department of Critical Care, King’s College Hospital NHS Foundation Trust, London, UK; 9] Department of Anaesthesia and Intensive Care, The Chinese University of Hong Kong, Shatin, Hong Kong SAR, China; 10 Department of Anesthesiology, Critical Care and Pain Medicine, Hadassah Medical Organization and Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.

Received: 2 February 2022 Accepted: 21 March 2022
Published online: 13 April 2022

References
1. Cook D, Rocker G. Dying with dignity in the intensive care unit. N Engl J Med. 2014;370:2506–14.
2. Vincent JL, Marshall JC, Nenmendys-Silva SA, François B, Martin-Loeches I, Lipman J, et al; ICON investigators. Assessment of the worldwide burden of critical illness: the intensive care over nations (ICON) audit. Lancet Respir Med. 2014;2:380–6.
3. Sprung CL, Cohen SL, Sjöqvist F, Baras M, Bulow HH, Hovilehto S, et al; Ethics Study Group. End-of-life practices in European intensive care units: the Ethics Study. JAMA. 2003;290:790–7.
4. Sprung CL, Ricou B, Hartog CS, Maia P, Mentzelopoulos SD, Weiss M, et al. Changes in end-of-life practices in European intensive care units from 1999 to 2016. JAMA. 2019;322:1692–1704. Erratum in: JAMA. 2019;322:1718.
5. Avidan A, Sprung CL, Schefold JC, Ricou B, Hartog CS, Nates JL, et al; ETHICUS-2 Study Group. Variations in end-of-life practices in intensive care units worldwide (ETHICUS-2): a prospective observational study. Lancet Respir Med. 2021; S2213-2600(21)00261-7.
6. Ko DN, Blinderman CD. Withholding and withdrawing life-sustaining treatment (including artificial nutrition and hydration). In: Cherry N, Fallon M, Kaasa S, Portenoy RK, Currow DC, editors. Oxford textbook
members and nurses for patients dying in US and Dutch ICUs. Chest. 2017;151:298–307.

49. Phua J, Joynt GM, Nishimura M, Deng Y, Myatra SN, Chan YH, et al; ACME Study Investigators and the Asian Critical Care Clinical Trials Group. Withholding and withdrawal of life-sustaining treatments in intensive care units in Asia. JAMA Intern Med. 2015;175:363–71. Erratum in: JAMA Intern Med. 2015;175:1248.

50. Collier J, Kelsberg G, Safaran S. Clinical Inquiries: How well do POLST forms assure that patients get the end-of-life care they requested? J Fam Pract. 2018;67:249–51.

51. Andorno R, Biler-Andorno N, Brauer S. Advance health care directives: towards a coordinated European policy? Eur J Health Law. 2009;16:207–27.

52. Sulmasy DP. Italy's new advance directive law: when in Rome. . . . . JAMA Intern Med. 2018;178:607–8.

53. Ciliberti R, Gorini I, Gazzaniga V, De Stefano F, Gulino M. The Italian law on informed consent and advance directives: new rules of conduct for the autonomy of doctors and patients in end-of-life care. J Crit Care. 2018;48:178–82.

54. Evans N, Bausewein C, Meñaca A, Andrew EV, Higginson IJ, Harding R, et al; project PRISMA. A critical review of advance directives in Germany: attitudes, use and healthcare professionals' compliance. Patient Educ Couns. 2012;87:277–88.

55. Bolcato M, Feola A, Sanavio M, Amadasi A, Crenna S, Landi G, et al. The state of knowledge of young Italian medicolegal doctors on the law of provisions for informed consent and advance treatment directives: a multi-centric survey two years after the enactment of Law 219 of 2017. Acta Biomed. 2020;92:e2021005.

56. Tolle SW, Teno JM. Lessons from Oregon in embracing complexity in end-of-life care. N Engl J Med. 2017;376:1078–82.

57. Petrova M, Riley J, Abel J, Barclay S. Crash course in EPaCCS (Electronic Palliative Care Coordination Systems): 8 years of successes and failures in patient data sharing to learn from. BMJ Support Palliat Care. 2018;8:447–55.

58. Park SY, Lee B, Seon JY, Oh IH. A national study of life-sustaining treatments in South Korea: what factors affect decision-making? Cancer Res Treat. 2021;53:593–600.

59. Scheunemann LP, Ernecco NC, Buddadhumaruk P, Carson SS, Hough CL, Curtis JR, et al. Clinician-family communication about patients' values and preferences in intensive care units. JAMA Intern Med. 2019;179:676–84.

60. Sengupta J, Chatterjee SC. Dying in intensive care units of India: commentaries on policies and position papers on palliative and end-of-life care. J Crit Care. 2017;39:11–7.

61. Lilley EJ, Williams KJ, Schneider EB, Hammouda K, Salim A, Haider AH, et al. Intensity of treatment, end-of-life care, and mortality for older patients with severe traumatic brain injury. J Trauma Acute Care Surg. 2016;80:998–1004.

62. Wilkinson DJ, Truog RD. The luck of the draw: physician-related variability in end-of-life decision-making in intensive care. Intensive Care Med. 2013;39:1128–32.

63. Schneiderman LJ, Gilmer T, Teetzl HD, Dugan DO, Blustein J, Cranford R, et al. Effect of ethics consultations on nonbeneficial life-sustaining treatments in the intensive care setting: a randomized controlled trial. JAMA. 2003;290:1166–72.

64. Löfmark R, Nilstun T, Cartwright C, Fischer S, van der Heide A, Mortier F, et al; EURELD Consortium. Physicians’ experiences with end-of-life decision-making: survey in 6 European countries and Australia. BMC Med. 2008;6:4.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.